Chemotherapy for Advanced-Stage Non–Small Cell Lung Cancer
Authors:
- Daniel MorgenszternDMDaniel Morgensztern
- 1 September 2015
- journal article
- review article
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 21 (5) , 366-370
Abstract
Use of platinum-based chemotherapy doublets is the standard of care for patients with advanced-stage non-small cell lung cancer, being associated with improved survival compared with best supportive care in fit patients with good performance status. Randomized studies showed that the addition of monoclonal antibodies against vascular endothelial growth factor receptor or epidermal growth factor receptor may increase the survival compared to chemotherapy alone. Patients with either advanced age or poor performance status can also benefit from chemotherapy. Docetaxel with or without ramucirumab, pemetrexed, and erlotinib are approved for previously treated patients. New treatment approaches are needed to improve the outcomes in this patient population.Keywords
This publication has 51 references indexed in Scilit:
- Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialThe Lancet Oncology, 2013
- Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Annals of Oncology, 2010
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled TrialsJournal of Clinical Oncology, 2008
- Phase III Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: The Swedish Lung Cancer Study GroupJournal of Clinical Oncology, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Docetaxel Versus Docetaxel Plus Cisplatin As Front-Line Treatment of Patients With Advanced Non—Small-Cell Lung Cancer: A Randomized, Multicenter Phase III TrialJournal of Clinical Oncology, 2004
- Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinomaCancer, 1998
- Cisplatin-Cyclophosphamide-Mitomycin Combination Chemotherapy With Supportive Care Versus Supportive Care Alone for Treatment of Metastatic Non-Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 1993
- Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinomaCancer, 1982